Ben W. J. Mol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ben W. J. Mol has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Fulco van der Veen
Centre for Reproductive Medicine, Academic Medical Centre, University of Amsterdam, 1100 DD Amsterdam, the Netherlands
12 shared publications Patrick M.M Bossuyt
7 shared publicationsFulco van der Veen
Centre for Reproductive Medicine, Academic Medical Centre, 1100 DE Amsterdam, The Netherlands
6 shared publications- Eva Pajkrt
Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, The Netherlands
5 shared publications P.G.A. Hompes
Department of Obstetrics and Gynaecology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
5 shared publicationsDouwe J Hemrika
Department of Obstetrics and Gynaecology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
4 shared publications
Latest Publications
- 1 October 2018
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 73 (10) , 568-570
Cost-effectiveness of Diagnostic Testing Strategies Including Cervical-Length Measurement and Fibronectin Testing in Women With Symptoms of Preterm Labor
- 1 October 2018
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 73 (10) , 568-570
Cost-effectiveness of Diagnostic Testing Strategies Including Cervical-Length Measurement and Fibronectin Testing in Women With Symptoms of Preterm Labor
- 26 June 2015
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 33 (01) , 040-046
Midpregnancy Cervical Length in Nulliparous Women and its Association with Postterm Delivery and Intrapartum Cesarean Delivery
Objective To evaluate the association between midpregnancy cervical length and postterm delivery and cesarean delivery during labor. Study Design In a multicenter cohort study, cervical length was measured in low-risk singleton pregnancies between 16 and 22 weeks of gestation. From this cohort, we identified nulliparous women who delivered beyond 34 weeks and calculated cervical length quartiles. We performed logistic regression to compare the risk of postterm delivery and intrapartum cesarean delivery to cervical length quartiles, using the lowest quartile as a reference. We adjusted for induction of labor, maternal age, ethnicity, cephalic position, preexisting hypertension, and gestational age at delivery. Results We studied 5,321 nulliparous women. Women with cervical length in the 3rd and 4th quartile were more likely to deliver at 42þ0 to 42þ6 weeks (adjusted odds ratio [aOR] 2.02, 95% confidence interval [CI] 1.07–3.79 and aOR 1.97, 95% CI 1.06–3.67, respectively). The frequency of intrapartum cesarean delivery increased with cervical length quartile from 9.4% in the 1st to 14.9% in the 4th quartile (p ¼ 0.01). This increase was only present in intrapartum cesarean delivery because of failure to progress and not because of fetal distress. Conclusion The longer the cervix atmidtrimester the higher the risk of both postterm delivery and intrapartum cesarean delivery.A. J. van der Ven, M. A. van Os, C. E. Kleinrouweler, C. J. M. Verhoeven, E. de Miranda, P. M. Bossuyt, C. J. M. de Groot, M. C. Haak, E. Pajkrt, B. W. J. Mol, B. M. Kazemie
- 26 June 2015
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 33 (01) , 040-046
Midpregnancy Cervical Length in Nulliparous Women and its Association with Postterm Delivery and Intrapartum Cesarean Delivery
Objective To evaluate the association between midpregnancy cervical length and postterm delivery and cesarean delivery during labor. Study Design In a multicenter cohort study, cervical length was measured in low-risk singleton pregnancies between 16 and 22 weeks of gestation. From this cohort, we identified nulliparous women who delivered beyond 34 weeks and calculated cervical length quartiles. We performed logistic regression to compare the risk of postterm delivery and intrapartum cesarean delivery to cervical length quartiles, using the lowest quartile as a reference. We adjusted for induction of labor, maternal age, ethnicity, cephalic position, preexisting hypertension, and gestational age at delivery. Results We studied 5,321 nulliparous women. Women with cervical length in the 3rd and 4th quartile were more likely to deliver at 42þ0 to 42þ6 weeks (adjusted odds ratio [aOR] 2.02, 95% confidence interval [CI] 1.07–3.79 and aOR 1.97, 95% CI 1.06–3.67, respectively). The frequency of intrapartum cesarean delivery increased with cervical length quartile from 9.4% in the 1st to 14.9% in the 4th quartile (p ¼ 0.01). This increase was only present in intrapartum cesarean delivery because of failure to progress and not because of fetal distress. Conclusion The longer the cervix atmidtrimester the higher the risk of both postterm delivery and intrapartum cesarean delivery.A. J. van der Ven, M. A. van Os, C. E. Kleinrouweler, C. J. M. Verhoeven, E. de Miranda, P. M. Bossuyt, C. J. M. de Groot, M. C. Haak, E. Pajkrt, B. W. J. Mol, B. M. Kazemie
- 1 April 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (4) , 200-201
Ten-Year Follow-Up of a Randomized Controlled Trial Comparing Bipolar Endometrial Ablation With Balloon Ablation for Heavy Menstrual Bleeding
- 1 April 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (4) , 200-201
Ten-Year Follow-Up of a Randomized Controlled Trial Comparing Bipolar Endometrial Ablation With Balloon Ablation for Heavy Menstrual Bleeding
- 1 April 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (4) , 193-195
Relationship of Isolated Single Umbilical Artery to Fetal Growth, Aneuploidy, and Perinatal Mortality
The umbilical cord normally contains 2 arteries and a single vein. When an umbilical artery is absent, the condition is called single umbilical artery (SUA). The reported prevalence of SUA varies from 0.5% at the second-trimester prenatal ultrasound and in umbilical cord specimens from live-born infants to 2.1% in fetal deaths, autopsies, or aborted fetuses. Approximately 33% of fetuses with SUA have additional structural anomalies, and 10% are affected with aneuploidy. In ~65% of cases, SUA seems to be an isolated finding. In pregnancies with an apparently isolated SUA (iSUA), aneuploidy or fetal size (small for gestational age [SGA]) may become apparent later in pregnancy or at birth. This systematic review was undertaken to assess outcome of iSUA diagnosed at the midtrimester ultrasound scan and to determine whether data are sufficient to determine appropriate management of pregnancies with diagnosed iSUA. MEDLINE, EMBASE, and the Cochrane Library databases were searched for articles reporting on SUA. Randomized controlled trials, cohort studies, and case-control studies were eligible if they described 30 or more cases of apparent iSUA identified by ultrasound before a mean gestational age of 24 weeks. All studies that allowed construction of a 2 × 2 table were included, with the incidence of the outcome of interest in SUA fetuses and 3-vessel cord fetuses. Quantitative data on the outcome variables included incidence of SGA and perinatal mortality, median or mean birth weight, and frequency of aneuploidy. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined for the occurrence of SGA, perinatal mortality, and frequency of aneuploidy in iSUA fetuses compared with those in 3-vessel cord fetuses. Of 449 articles, the final analysis included 3 cohort and 4 case-control studies, reporting on 68 and 297 cases of apparent iSUA, with a total of 982 patients with an iSUA. The mean gestational age at diagnosis of SUA was 19.0 to 24.3 weeks. A non–statistically significant association was found between iSUA and SGA at birth (OR for SGA in fetuses with iSUA, 1.6; 95% CI, 0.97–2.6; P = 0.06), with ORs in the cohort studies ranging from 1.1 to 3.3. In 3 of the case-control studies, iSUA fetuses did not have significantly lower mean birth weights compared with control fetuses (mean weight, 3154 vs 3176 g; mean difference, 51 g; 95% CI, −154.7 to 52.6 g; P = 0.33). The OR for preterm birth in fetuses with an iSUA compared with control fetuses was 2.1 (95% CI, 1.4–3.2) for delivery before 37 weeks and 3.3 (95% CI, 1.4–7.7) for delivery before 34 weeks. Although there was a positive association between iSUA and increased perinatal mortality, it did not meet statistical significance (OR, 2.0; 95% CI, 0.9–4.2; P = 0.07). Among 695 iSUA cases reported in 16 studies, 4 cases of aneuploidy (0.58%) occurred; the mean maternal age was 30.1 years. These results indicate that iSUA is associated with a nonsignificant trend for increased risk for SGA and perinatal mortality. The relatively low birth weight in iSUA neonates may occur as a result of a relatively high prevalence of preterm birth. On the basis of this review, no firm conclusions can be drawn about the association between iSUA and aneuploidy. More large-scale, prospective cohort studies are necessary to clarify these associations and identify appropriate management protocols for iSUA fetuses.
- 1 April 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (4) , 193-195
Relationship of Isolated Single Umbilical Artery to Fetal Growth, Aneuploidy, and Perinatal Mortality
The umbilical cord normally contains 2 arteries and a single vein. When an umbilical artery is absent, the condition is called single umbilical artery (SUA). The reported prevalence of SUA varies from 0.5% at the second-trimester prenatal ultrasound and in umbilical cord specimens from live-born infants to 2.1% in fetal deaths, autopsies, or aborted fetuses. Approximately 33% of fetuses with SUA have additional structural anomalies, and 10% are affected with aneuploidy. In ~65% of cases, SUA seems to be an isolated finding. In pregnancies with an apparently isolated SUA (iSUA), aneuploidy or fetal size (small for gestational age [SGA]) may become apparent later in pregnancy or at birth. This systematic review was undertaken to assess outcome of iSUA diagnosed at the midtrimester ultrasound scan and to determine whether data are sufficient to determine appropriate management of pregnancies with diagnosed iSUA. MEDLINE, EMBASE, and the Cochrane Library databases were searched for articles reporting on SUA. Randomized controlled trials, cohort studies, and case-control studies were eligible if they described 30 or more cases of apparent iSUA identified by ultrasound before a mean gestational age of 24 weeks. All studies that allowed construction of a 2 × 2 table were included, with the incidence of the outcome of interest in SUA fetuses and 3-vessel cord fetuses. Quantitative data on the outcome variables included incidence of SGA and perinatal mortality, median or mean birth weight, and frequency of aneuploidy. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined for the occurrence of SGA, perinatal mortality, and frequency of aneuploidy in iSUA fetuses compared with those in 3-vessel cord fetuses. Of 449 articles, the final analysis included 3 cohort and 4 case-control studies, reporting on 68 and 297 cases of apparent iSUA, with a total of 982 patients with an iSUA. The mean gestational age at diagnosis of SUA was 19.0 to 24.3 weeks. A non–statistically significant association was found between iSUA and SGA at birth (OR for SGA in fetuses with iSUA, 1.6; 95% CI, 0.97–2.6; P = 0.06), with ORs in the cohort studies ranging from 1.1 to 3.3. In 3 of the case-control studies, iSUA fetuses did not have significantly lower mean birth weights compared with control fetuses (mean weight, 3154 vs 3176 g; mean difference, 51 g; 95% CI, −154.7 to 52.6 g; P = 0.33). The OR for preterm birth in fetuses with an iSUA compared with control fetuses was 2.1 (95% CI, 1.4–3.2) for delivery before 37 weeks and 3.3 (95% CI, 1.4–7.7) for delivery before 34 weeks. Although there was a positive association between iSUA and increased perinatal mortality, it did not meet statistical significance (OR, 2.0; 95% CI, 0.9–4.2; P = 0.07). Among 695 iSUA cases reported in 16 studies, 4 cases of aneuploidy (0.58%) occurred; the mean maternal age was 30.1 years. These results indicate that iSUA is associated with a nonsignificant trend for increased risk for SGA and perinatal mortality. The relatively low birth weight in iSUA neonates may occur as a result of a relatively high prevalence of preterm birth. On the basis of this review, no firm conclusions can be drawn about the association between iSUA and aneuploidy. More large-scale, prospective cohort studies are necessary to clarify these associations and identify appropriate management protocols for iSUA fetuses.
- 1 February 2014
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 28 (2) , 239-245
Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands
- 1 February 2014
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 28 (2) , 239-245
Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands
- 6 August 2013
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 42 (3) , 257-267
Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis
Not availableC. E. Kleinrouweler, P. M. M. Bossuyt, B. Thilaganathan, K. C. Vollebregt, J. Arenas Ramrez, A. Ohkuchi, K. L. Deurloo, M. Macleod, A. E. Diab, H. Wolf, J. A. M. van der Post, B. W. J. Mol and E. Pajkr
- 6 August 2013
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 42 (3) , 257-267
Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis
Not availableC. E. Kleinrouweler, P. M. M. Bossuyt, B. Thilaganathan, K. C. Vollebregt, J. Arenas Ramrez, A. Ohkuchi, K. L. Deurloo, M. Macleod, A. E. Diab, H. Wolf, J. A. M. van der Post, B. W. J. Mol and E. Pajkr
- Open Access
- 23 April 2013
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 28 (7) , 1737-1742
Economic analysis of chromosome testing in couples with recurrent miscarriage to prevent handicapped offspring
Which strategy is least expensive to prevent the birth of a handicapped child in couples with recurrent miscarriage (RM); parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents, or amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status? For virtually all couples with RM amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status is less expensive in preventing the birth of a handicapped child than parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents. One of the causes of RM is a balanced chromosome abnormality in one of the partners. If one of the partners is carrier of a balanced structural chromosomal abnormality, the risk of offspring with an unbalanced structural chromosome abnormality is increased. Like all couples, couples with RM also have an age-dependent risk for fetal aneuploidy, of which trisomy 21 is most common. Model-based economic analysis to compare costs and effects of two strategies in couples with RM to prevent the birth of a handicapped child in case of ongoing pregnancy. Comparison of two strategies in women with RM: strategy (I) parental chromosome analysis followed by amniocentesis in pregnancy in case of carrier status of one of the parents and strategy (II) amniocentesis in all ongoing pregnancies without the knowledge of carrier status. No testing was the reference strategy. Data on probabilities and costs were derived from the literature. Incremental costs and effects were calculated [incremental cost-effectiveness ratio (ICER)]. Effectiveness was expressed as the number of prevented births of handicapped child equivalents compared with no testing. In these calculations, the birth of a handicapped child was valued 10 times worse than the loss of a viable pregnancy due to amniocentesis. Depending on the risk for carrier status, the ICER for Strategy I (parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents) varied between €226 000 and €6 556 000 per prevented handicapped child equivalent. For Strategy II (amniocentesis in all ongoing pregnancies without the knowledge of carrier status), the ICER varied between €2000 and €233 000 per prevented handicapped child equivalent. Strategy I was less expensive than Strategy II only for a small subgroup of couples with maternal age <23 years, three or more previous miscarriages and a family history of RM. Our analysis is not a plea for amniocentesis in all women with RM. Individual risk assessment with serum markers and nuchal translucency is probably more effective at lower cost. This analysis can be used by clinicians to explain the chances of adverse pregnancy outcome in couples with RM, as well as by policy makers in health-care economics. Future guidelines on RM might be more restrictive from the perspective of the limited health-care resources that we have available. Supported by ZonMW. ZonMW had no role in designing the study, data collection, analysis and interpretation of data or writing of the report. Competing interests: none.
- 23 April 2013
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 28 (7) , 1737-1742
Open AccessEconomic analysis of chromosome testing in couples with recurrent miscarriage to prevent handicapped offspring
Which strategy is least expensive to prevent the birth of a handicapped child in couples with recurrent miscarriage (RM); parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents, or amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status? For virtually all couples with RM amniocentesis in all ongoing pregnancies without the knowledge of parental carrier status is less expensive in preventing the birth of a handicapped child than parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents. One of the causes of RM is a balanced chromosome abnormality in one of the partners. If one of the partners is carrier of a balanced structural chromosomal abnormality, the risk of offspring with an unbalanced structural chromosome abnormality is increased. Like all couples, couples with RM also have an age-dependent risk for fetal aneuploidy, of which trisomy 21 is most common. Model-based economic analysis to compare costs and effects of two strategies in couples with RM to prevent the birth of a handicapped child in case of ongoing pregnancy. Comparison of two strategies in women with RM: strategy (I) parental chromosome analysis followed by amniocentesis in pregnancy in case of carrier status of one of the parents and strategy (II) amniocentesis in all ongoing pregnancies without the knowledge of carrier status. No testing was the reference strategy. Data on probabilities and costs were derived from the literature. Incremental costs and effects were calculated [incremental cost-effectiveness ratio (ICER)]. Effectiveness was expressed as the number of prevented births of handicapped child equivalents compared with no testing. In these calculations, the birth of a handicapped child was valued 10 times worse than the loss of a viable pregnancy due to amniocentesis. Depending on the risk for carrier status, the ICER for Strategy I (parental chromosome analysis followed by amniocentesis in case of carrier status of one of the parents) varied between €226 000 and €6 556 000 per prevented handicapped child equivalent. For Strategy II (amniocentesis in all ongoing pregnancies without the knowledge of carrier status), the ICER varied between €2000 and €233 000 per prevented handicapped child equivalent. Strategy I was less expensive than Strategy II only for a small subgroup of couples with maternal age <23 years, three or more previous miscarriages and a family history of RM. Our analysis is not a plea for amniocentesis in all women with RM. Individual risk assessment with serum markers and nuchal translucency is probably more effective at lower cost. This analysis can be used by clinicians to explain the chances of adverse pregnancy outcome in couples with RM, as well as by policy makers in health-care economics. Future guidelines on RM might be more restrictive from the perspective of the limited health-care resources that we have available. Supported by ZonMW. ZonMW had no role in designing the study, data collection, analysis and interpretation of data or writing of the report. Competing interests: none.
- Open Access
- 1 December 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (12) , 751-753
Should Cervical Favourability Play a Role in the Decision for Labour Induction in Gestational Hypertension or Mild Pre-eclampsia at Term? An Exploratory Analysis of the HYPITAT Trial
- 1 December 2012
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 67 (12) , 751-753
Open AccessShould Cervical Favourability Play a Role in the Decision for Labour Induction in Gestational Hypertension or Mild Pre-eclampsia at Term? An Exploratory Analysis of the HYPITAT Trial
- 31 December 2011
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 18 (6) , S34
Longterm Follow-Up of a Randomized Controlled Trial Comparing NovaSure and Hydrothermablation for Dysfunctional Uterine Bleeding
- 31 December 2011
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 18 (6) , S34
Longterm Follow-Up of a Randomized Controlled Trial Comparing NovaSure and Hydrothermablation for Dysfunctional Uterine Bleeding